AzTrials
AzTrials

Psoriatic ArthritisPhase 3OPAL BEYONDNCT01882439

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

A Phase 3 study testing Tofacitinib in people with Psoriatic Arthritis, run by Pfizer at 125 sites in 14 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis
What is being tested?
Tofacitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
395 participants
Where
125 sitesin 14 countries
Study dates
Aug 2013to Apr 2016
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
  • Active plaque psoriasis at screening
  • Inadequate efficacy or lack of toleration to previously administered TNF inhibitor

Who cannot join

  • Non-plaque forms of psoriasis (with exception of nail psoriasis)
  • History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA

Trial locations and contacts

125 sites in 14 countries.

125 sites in 14 countries

United States43 sites
  • East Penn Rheumatology Associates, PC

    Bethlehem, Pennsylvania, 18015

  • Rheumatology Associates P.C.

    Birmingham, Alabama, 35205

  • St. Luke's Clinic - Rheumatology

    Boise, Idaho, 83702

  • St. Luke's Intermountain Research Center

    Boise, Idaho, 83702

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115

  • Low Country Rheumatology, PA

    Charleston, South Carolina, 29406

  • Cincinnati Rheumatic Disease Study Group, Inc.

    Cincinnati, Ohio, 45219

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106

  • Adriana M. Pop-Moody, M.D., Clinic, P.A.

    Corpus Christi, Texas, 78404

  • Medvin Clinical Research

    Covina, California, 91723

  • Pioneer Research Solutions, Inc.

    Cypress, Texas, 77429

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • St. Paul Rheumatology, PA

    Eagan, Minnesota, 55121

  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare

    Fullerton, California, 92835

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona, 85306

  • Klein & Associates, M.D., P.A.

    Hagerstown, Maryland, 21740

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama, 35801-4414

  • Arthritis Clinic

    Jackson, Tennessee, 38305

  • West Tennessee Research Institute

    Jackson, Tennessee, 38305

  • Dartmouth-Hitchcock Medical Center (DHMC)

    Lebanon, New Hampshire, 03756

  • Bluegrass Community Research, Inc

    Lexington, Kentucky, 40504

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516

  • Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California, 90095

  • UCLA David Geffen School of Medicine

    Los Angeles, California, 90095

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio, 44130

  • Rheumatology Associates of Central Florida, PA

    Orlando, Florida, 32806

  • Millennium Research

    Ormond Beach, Florida, 32174

  • Arthritis Center, Inc.

    Palm Harbor, Florida, 34684

  • Integral Rheumatology & Immunology Specialists (IRIS)

    Plantation, Florida, 33324

  • Drug Shipment/Storage: Investigational Drug Services

    Salt Lake City, Utah, 84112

  • University of Utah Hospital & Clinics

    Salt Lake City, Utah, 84132

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Dynacare Laboratories

    Seattle, Washington, 98122

  • Seattle Rheumatology Associates

    Seattle, Washington, 98122

  • Swedish Medical Center

    Seattle, Washington, 98122

  • Clayton Medical Research

    St Louis, Missouri, 63117

  • Stanford Hospital and Clinics

    Stanford, California, 94305

  • New England Research Associates, LLC

    Trumbull, Connecticut, 06611

  • The Center For Rheumatology And Bone Research

    Wheaton, Maryland, 20902

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

  • Florida Medical Clinic, P.A.

    Zephyrhills, Florida, 33542

Other trials in United States

Mexico18 sites
  • Christus Muguerza del parque, S.A de C.V

    Chihuahua City, 31000

  • Investigacion y Biomedicina de Chihuahua

    Chihuahua City, 31000

  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C

    Culiacán, Sinaloa, 80000

  • Sanatorio CEMSI Chapultepec (For Emergencies Only)

    Culiacán, Sinaloa, 80040

  • Hospital General de Culiacan "Dr. Bernardo J. Gastelum"

    Culiacán, Sinaloa, 80230

  • Centro Integral en Reumatologia SA de CV

    Guadalajara, Jalisco, 44160

  • Grupo Santa Bernardette S.A. de C.V.

    Guadalajara, Jalisco, 44200

  • Star Medica S.A. de C.V. (For Emergencies Only)

    Merdia, Yucatán, 97133

  • Institute Medico Panamericano, S.A. de C.V. (For Emergencies Only)

    Mérida, Yucatán, 97000

  • Unidad Reumatologica Las Americas SCP

    Mérida, Yucatán, 97000

  • Centro de Investigacion Clinica Pensiones

    Mérida, Yucatán, 97070

  • Centro Multidisciplinario para el Desarrollo

    Mérida, Yucatán, 97130

  • Hospital Star Medica Merida (For Emergencies Only)

    Mérida, Yucatán, 97133

  • Hospital Angeles Clinica Londres

    Mexico City, D.F, 06700

  • Grupo Medico Camino S.C.

    Mexico City, Mexico City, 03310

  • CLIDITER, S.A. de C.V.

    Mexico City, Mexico City, 06700

  • Universidad La Salle AC

    Mexico City, Mexico City, 14000

  • Medica Sur, S.A.B. de C.V. (For Emergencies Only)

    Mexico City, Mexico City, 14050

Other trials in Mexico

Germany10 sites
  • Rheumazentrum Prof. Dr. med Gunther Neeck

    Bad Doberan, 18209

  • Charite Universitatsmedizin Berlin - Campus Charite Mitte

    Berlin, 10117

  • Rheumapraxis Steglitz

    Berlin, 12161

  • Schlosspark-Klinik

    Berlin, 14059

  • University Hospital of Cologne

    Cologne, 50937

  • Universitaetsklinikum Erlangen, Medizinische Klinik 3

    Erlangen, 91054

  • CIRI - Centrum für innovative Diagnostik und Therapie Rheumatologie/Immunologie (GmbH)

    Frankfurt am Main, 60528

  • Medizinische Universitatsklinik Freiburg

    Freiburg im Breisgau, 79106

  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes

    Homburg, 66421

  • Elisabeth Klinik Bigge

    Olsberg, 59939

Other trials in Germany

Poland9 sites
  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzez

    Elblag, 82-300

  • Centrum Radiologii for X-Ray only

    Elblag, 82-300

  • NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela

    Elblag, 82-300

  • Wojewodzki Szpital Zespolony Zaklad Radiologii

    Elblag, 82-300

  • Przychodnia Specjalistyczna Lekarskiej Spozielni Pracy "Medica" for X-Ray Only

    Grodzisk Mazowiecki, 05-825

  • Specjalistyczne Gabinety Lekarskie "DERMED" Anna Kaszuba

    Lodz, 90-265

  • NZOZ Lecznica MAK-MED S.C.

    Nadarzyn, 05-830

  • Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj

    Poznan, 61-397

  • Reumatika Centrum Reumatologii nzoz

    Warsaw, 02-691

Other trials in Poland

Spain8 sites
  • Complejo Hospitalario Universitario A Coruna

    A Coruña, 15006

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008

  • Hospital Clinico de Santiago

    Santiago de Compostela, A Coruna, 15706

  • Hospital Universitario Virgen Macarena

    Seville, 41009

  • Hospital Sierrallana

    Torrelavega, Cantabria, 39300

  • Hospital Universitaro Y Politecnico La Fe

    Valencia, 46026

Other trials in Spain

Russia7 sites
  • State Autonomic Healthcare Institution City Clinical Hospital # 7

    Kazan', Republic of Tatarstan, Russia, 420103

  • SBIH of Moscow "City Clinical Hospital#1 n. a. N.I. Pirogov" of the Healthcare Department of Moscow

    Moscow, 119049

  • City Neurological Centre "SibNeyroMed", LLC

    Novosibirsk, 630091

  • Limited Liability Company Consultative Diagnostic Rheumatology Center "Healthy Joints"

    Novosibirsk, 630099

  • Regional State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a.

    Petrozavodsk, Karelia Republic, 185019

  • State Budget Educational Institution of Highest Professional Education

    Tomsk, 634050

  • State Institution of Healthcare of Yaroslavl Region

    Yaroslavl, 150003

Other trials in Russia

United Kingdom7 sites
  • Royal United Hospitals NHS Foundation Trust

    Bath, BA1 1RL

  • Bradford Royal Infirmary, BTHFT

    Bradford, West Yorkeshire, BD9 6RJ

  • Bradford Teaching Hospitals NHS Foundation Trust

    Bradford, BD5 0NA

  • The Dudley Group NHS Foundation Trust

    Dudley, West Midlands, DY1 2HQ

  • Barking Havering and Redbridge University Hospitals NHS Trust

    Goodmayes, Essex, IG3 8YB

  • Barking, Havering and Redbridge University Hospitals NHS Trust

    Romford, Essex, RM7 0AG

  • York Hospital, York Teaching Hospital NHS Foundation Trust

    York, YO31 8HE

Other trials in United Kingdom

Brazil6 sites
  • Clinica Medica Bonfiglioli Ltda. / Clinica Bonfiglioli

    Campinas, São Paulo, 13015-001

  • Radiologia Clínica de Campinas - RCC (Images only)

    Campinas, São Paulo, 13015-240

  • CETAC - DIAGNOSTICO POR IMAGEM (image only)

    Curitiba, Paraná, 80240-160

  • EDUMED - Educacao em Saude SS LTDA.

    Curitiba, Paraná, 80440-080

  • CMIP: Centro Mineiro de Pesquisa Ltda /

    Juiz de Fora, Minas Gerais, 36010-570

  • Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS

    Porto Alegre, Rio Grande do Sul, 90035-003

Other trials in Brazil

Belgium5 sites
  • Hospital Erasme - Clinique Universitaire de Bruxelles

    Brussels, 1070

  • ReumaClinic

    Genk, 3600

  • Universitair Ziekenhuis Gent

    Ghent, 9000

  • University Hospital Leuven, Department of Rheumatology

    Leuven, 3000

  • ZNA Jan Palfijn

    Merksem, 2170

Other trials in Belgium

Taiwan5 sites
  • Buddhist Dalin Tzu Chi General Hospital

    Chiayi City, 62247

  • Chang Gung Medical Foundation-Kaohsiung Branch

    Kaohsiung City, 83301

  • Chung Shan Medical University Hospital

    Taichung, 40201

  • China Medical University Hospital

    Taichung, 40447

  • Taipei Veterans General Hospital

    Taipei, Taiwan Roc, 11217

Other trials in Taiwan

Australia3 sites
  • Royal Prince Alfred Hospital, Rheumatology Department

    Camperdown, New South Wales, 2050

  • Emeritus Research Pty Ltd

    Malvern East, Victoria, 3145

  • Rheumatology Research Unit

    Maroochydore, Queensland, 4558

Other trials in Australia

France2 sites
  • Hopital Avicenne

    Bobigny, 93000

  • Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie

    Corbeil-Essonnes, Cedex, 91106

Other trials in France

Czechia1 site
  • Medical Plus s.r.o.

    Uherské Hradiště, 68601

Other trials in Czechia

Slovakia1 site
  • MEDMAN s.r.o. - reumatologicka ambulancia

    Martin, 036 01

Other trials in Slovakia

About this study

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor

To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.

Being tested
Tofacitinib, Placebo
Keywords
psoriatic arthritis, tofacitinib, ACR20, HAQ-DI, TNF inhibitor failure
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TofacitinibDrug

    tablets, 5 mg BID x 6 months

  • TofacitinibDrug

    tablets, 10 mg BID x 6 months

  • PlaceboOther

    tablets, to match tofacitinib 5 mg BID x 3 months

  • TofacitinibDrug

    tablets, 5 mg BID x 3 months

  • PlaceboOther

    tablets, to match tofacitinib 10 mg BID x 3 months

  • TofacitinibDrug

    tablets, 10 mg BID x 3 months

Study groups in NCT01882439
Study groupRoleWhat they receive
Treatment Sequence AExperimentalTofacitinib 5 mg BID for 6 months
Receives: Drug: Tofacitinib
Treatment Sequence BExperimentalTofacitinib 10 mg BID for 6 months
Receives: Drug: Tofacitinib
Treatment Sequence CPlacebo comparatorPlacebo for 3 months then tofacitinib 5 mg BID for 3 months
Receives: Other: Placebo; Drug: Tofacitinib
Treatment Sequence DPlacebo comparatorPlacebo for 3 months then tofacitinib 10 mg BID for 3 months
Receives: Other: Placebo; Drug: Tofacitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, Health Assessment Questionnaire - Disability Index (HAQ-DI), and C-reactive protein (CRP).

    Measured: Month 3

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3

    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability.

    Measured: Month 3

Secondary outcomes (36)
  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6

    ACR50 was calculated as a ≥50% improvement from baseline in tender /painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Measured: Week 2 and Months 1, 2, 3, 4, and 6

  2. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, and 6

    ACR70 was calculated as a ≥70% improvement from baseline in tender /painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Measured: Week 2 and Months 1, 2, 3, 4, and 6

  3. Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Week 2 and Months 1, 2, 4, and 6

    ACR20 was calculated as a ≥20% improvement from baseline in tender /painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. n=number of responders.

    Measured: Week 2 and Months 1, 2, 4, and 6

  4. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Week 2 and Months 1, 2, 4, and 6

    The HAQ-DI assesses the difficulty a patient has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability. Overall score was computed as the sum of the domain scores divided by the number of domains answered. The total possible score ranged from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. Higher overall score indicates greater disability. n=number of participants evaluable at each visit.

    Measured: Week 2 and Months 1, 2, 4, and 6

  5. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components: C-reactive Protein (CRP) Levels: Month 3

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Measured: Month 3

  6. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Assessment of Arthritis Pain: Month 3

    Participants assessed the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

    Measured: Month 3

  7. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Patient's Global Assessment of Arthritis: Month 3

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

    Measured: Month 3

  8. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Physician's Global Assessment of Arthritis: Month 3

    The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

    Measured: Month 3

  9. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Swollen Joint Count: Month 3

    Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

    Measured: Month 3

  10. Change From Baseline in American College of Rheumatology (ACR) Response Criteria Components Score: Tender/Painful Joint Count: Month 3

    Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

    Measured: Month 3

  11. Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC): Week 2, Months 1, 2, 3, 4, and 6

    The PsARC covers 4 measures: Tender joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count. n=number of responders.

    Measured: Week 2, Months 1, 2, 3, 4, and 6

  12. Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response: Months 1, 3, and 6

    The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine the PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). n=number of participants evaluable at each visit.

    Measured: Months 1, 3, and 6

  13. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response: Months 1, 3, and 6

    PASI determines psoriasis severity based on lesion severity and percentage of body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, and scaling evaluated separately for the head and neck, upper limbs, trunk, and lower limbs and then rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis and is assigned a numerical score: 0=no involvement; 1=0% to 9%; 2=10% to 29%; 3=30% to 49%; 4=50% to 69%; 5=70% to 89%; 6=90% to 100%. In each area, the sum of the severity rating scores is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the 4 body areas is the PASI. PASI75 is defined as a 75% reduction from baseline in PASI. n=number of responders.

    Measured: Months 1, 3, and 6

  14. Change From Baseline in Dactylitis Severity Score (DSS): Months 1, 3, and 6

    Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, and 6

  15. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Months 1, 3, and 6

    The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, and 6

  16. Change From Baseline in the Leeds Enthesitis Index (LEI): Months 1, 3, and 6

    Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for a total score of 0-6. Higher score indicates greater severity of enthesitis. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, and 6

  17. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Component Summary Score: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  18. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Component Summary Score: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better mental health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  19. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Physical Functioning Domain: Months 1, 3, 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represent levels \& kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher physical functioning domain score represents better physical functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  20. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-physical Domain: Months 1, 3, 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Items in the role-physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-physical domain score represents better role-physical functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  21. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Bodily Pain Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher bodily pain domain score represents less bodily pain. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  22. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): General Health Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher general health domain score represents better general health perceptions. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  23. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Vitality Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher vitality domain score represents better vitality. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  24. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Social Functioning Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher social functioning domain score represents better social functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  25. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Role-emotional Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher role-emotional domain score represents better role-emotional functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  26. Change From Baseline in the Short-Form-36 Health Survey Version 2, Acute Components (SF-36v2 Acute): Mental Health Domain: Months 1, 3, 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based T-scores for both the SF36 version 2 \& SF36 health domain scales \& component summary measures have means of 50 \& standard deviations of 10. A higher mental health domain score represents better mental health functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  27. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  28. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-Care: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  29. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  30. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  31. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  32. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today: Months 1, 3, 6

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm VAS (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  33. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  34. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  35. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score: Months 1, 3, 6

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

  36. Change From Baseline in Score Evaluating Spondylitis Using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Months 1, 3, 6

    BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participants answered 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averaged the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity. n=number of participants evaluable at each visit.

    Measured: Months 1, 3, 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jun 2013 (estimated)
  2. Study startAug 2013
  3. Primary completionApr 2016
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
395 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01882439
Sponsor's protocol ID
A3921125
Other IDs
2013-001368-46
Acronym
OPAL BEYOND
Status last verified
Sep 2017
First submitted
18 Jun 2013
Last updated
15 Sep 2017
Data monitoring committee
Yes

Publications

  • Gossec L, Sellas A, Gruben DC, Valderrama M, Gomez S, Kinch C, Citera G. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials. Rheumatol Ther. 2025 Dec;12(6):1175-1186. doi: 10.1007/s40744-025-00800-7. Epub 2025 Oct 28.

    PubMed 41148555
  • Gladman D, Tillett W, Gruben D, Coates LC, Hahne S, Volkov M. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. RMD Open. 2025 Jun 3;11(2):e005250. doi: 10.1136/rmdopen-2024-005250.

    PubMed 40461265
  • Gladman DD, Dougados M, Marzo-Ortega H, Cadatal MJ, Agarwal E, Kinch CD, Nash P. Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis. Rheumatol Adv Pract. 2025 Jan 21;9(2):rkaf008. doi: 10.1093/rap/rkaf008. eCollection 2025.

    PubMed 40241921
  • Menon S, Shoji S, Tsuchiwata S, Fallon L, Kanik K. Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies. J Clin Pharmacol. 2025 Mar;65(3):369-377. doi: 10.1002/jcph.6147. Epub 2024 Oct 25.

    PubMed 39453735
  • Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Dona L Fleishaker, Mundayat R, Young P, Helliwell PS. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther. 2023 Aug 22;25(1):153. doi: 10.1186/s13075-023-03108-5.

    PubMed 37608391
  • Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ, Ogdie A, Polachek A, Gruben D, Cadatal MJ, Kinch C, Strand V. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023 Mar;9(1):e002718. doi: 10.1136/rmdopen-2022-002718.

    PubMed 36958766
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Schneeberger EE, Citera G, Nash P, Smolen JS, Mease PJ, Soriano ER, Helling C, Szumski AE, Mundayat R, de Leon DP. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. 2023 Feb;58:152134. doi: 10.1016/j.semarthrit.2022.152134. Epub 2022 Nov 13.

    PubMed 36476498
  • de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8.

    PubMed 36076054
  • Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022 Sep 1;6(1):68. doi: 10.1186/s41927-022-00298-4.

    PubMed 36045453
  • Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022 Aug;33(5):2614-2620. doi: 10.1080/09546634.2022.2060924. Epub 2022 Apr 11.

    PubMed 35385361
  • Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0.

    PubMed 35139908
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.

    PubMed 34921355

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tofacitinib in people with Psoriatic Arthritis, run by Pfizer at 125 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 125 sites in United States, Mexico, Germany, Poland, Spain and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Sep 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3 (time frame: Month 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01882439, which also lists 29 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in